France at odds with European medicines agency over Pill

France insisted Friday on restricting the prescription of newer-generation birth control pills even as Europe's medicines watchdog declared there was no evidence to merit a health warning.

Citing concerns over risks of from the so-called 3rd- and 4th-generation pills, France said it would limit prescriptions of these contraceptives and urged the European Union (EU) to follow suit.

French Marisol Touraine urged the EU to consider a restriction on prescribing the contraceptives and announced a French "directive" to achieve the same.

"We will ask Europe not to suspend but to modify" the prescription guidelines for the pills, said Dominique Maraninchi of the French medicines watchdog, who spoke alongside Touraine at a press conference.

The European Medicines Agency (EMA) earlier said there was no basis for changing guidelines.

"There is currently no new evidence that would suggest any change to the known safety profile of any combined contraceptives marketed today," the agency said in a statement from London.

"Therefore, there is no reason for any woman to stop using her contraception."

add to favorites email to friend print save as pdf

Related Stories

US reviews birth control pill safety over clot risk

May 31, 2011

The US Food and Drug Administration said Tuesday it is reviewing recently published studies which have pointed to an increased blood clot risk associated with a certain type of birth control pill.

Recommended for you

Have a cold? Don't ask your doctor for antibiotics

6 hours ago

Antibiotic resistance is a major threat to public health. Resistance makes it harder for physicians to treat infections and can increase the chance patients will die from an infection. What is more, the treatment ...

Powdered measles vaccine found safe in early clinical trials

Nov 25, 2014

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

Health care M&A leads global deal surge

Nov 23, 2014

In a big year for deal making, the health care industry is a standout. Large drugmakers are buying and selling businesses to control costs and deploy surplus cash. A rising stock market, tax strategies and ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.